Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific
暂无分享,去创建一个
T. Comery | Manuel Buttini | P. Seubert | D. Schenk | D. Games | W. Zago | F. Bard | Christopher Nishioka | G. Kinney | S. Gardai
[1] Grazia D'Onofrio,et al. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. , 2011, Current Alzheimer research.
[2] D. Selkoe,et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.
[3] K. Blennow,et al. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease , 2010, Alzheimer's & Dementia.
[4] S. Gandy. Testing the amyloid hypothesis of Alzheimer's disease in vivo , 2010, The Lancet Neurology.
[5] R. Sperling,et al. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease , 2010, Alzheimer disease and associated disorders.
[6] E. Chen-Dodson,et al. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons , 2010, Neurobiology of Aging.
[7] Xiaohua Douglas Zhang,et al. Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic Disruption , 2009, The Journal of Biological Chemistry.
[8] T. Comery,et al. Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease , 2009, The Journal of Biological Chemistry.
[9] B. Hyman,et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease , 2009, Neurobiology of Disease.
[10] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[11] R. Barbour,et al. Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice , 2008, The Journal of Neuroscience.
[12] M. Pangalos,et al. Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse , 2008, Neurodegenerative Diseases.
[13] D. Selkoe,et al. Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.
[14] R. Malinow,et al. AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss , 2006, Neuron.
[15] R. Hepler,et al. Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .
[16] D. Henze,et al. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. , 2006, Current topics in medicinal chemistry.
[17] E. Masliah,et al. β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[18] T. Comery,et al. Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[19] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[20] C. Finch,et al. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.
[21] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[22] G. Saggese,et al. Pubertal Changes in Biochemical Markers of Growth , 2003, Hormone Research in Paediatrics.
[23] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[24] R. Motter,et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Schenk. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.
[26] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[27] T. Morgan,et al. Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.
[28] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[29] R. Nicoll,et al. Dynamin-dependent endocytosis of ionotropic glutamate receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. , 2008, Neurobiology of aging.
[31] R. Hepler,et al. Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.
[32] E. Masliah,et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[33] T. Comery,et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[34] C. Finch,et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[35] D. Schenk. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. , 2002, Nature reviews. Neuroscience.